The 12,000 organ transplants performed in the U.S. each year are often successful only because the patients take a daily dose of cyclosporine. The drug keeps their immune systems from attacking and rejecting the foreign organs. But it is not perfect. Some 70% of patients getting a new liver, for example, still suffer rejection episodes. And many organ recipients face life- threatening side effects from cyclosporine, including an increased risk of cancer and heart disease.
Now a respected researcher who was one of the first to use cyclosporine may have found a better way to make transplants succeed. Dr. Thomas Starzl...
To continue reading:
or
Log-In
